Guardant Health stock hits 52-week high of $39.61 amid growth

Published 21/01/2025, 15:36
Guardant Health stock hits 52-week high of $39.61 amid growth
GH
-

Guardant Health (NASDAQ:GH) Inc. shares soared to a 52-week high of $39.61, continuing their momentum to reach $41.25, marking a significant milestone for the precision oncology company. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. This peak reflects a robust year-over-year growth, with the stock witnessing an impressive 57.88% increase in value over the past year. Investors have shown increased confidence in Guardant Health’s innovative approach to cancer diagnostics and treatment, propelling the stock to new heights. The company’s commitment to advancing its technology and expanding its market reach has driven substantial revenue growth of 29.2% over the last twelve months, resonating positively with the market sentiment. With the next earnings report scheduled for February 20, 2025, InvestingPro subscribers can access additional insights through comprehensive analysis and 8 more ProTips about Guardant Health’s financial health and growth prospects.

In other recent news, Guardant Health has made significant strides in its operations. The company’s Guardant Reveal test for colon cancer has gained expanded Medicare coverage, allowing for more comprehensive monitoring of colorectal cancer patients. This development is a notable expansion from the previous Medicare coverage, which was limited to early post-surgical testing.

In the field of analyst ratings, UBS has named Guardant Health as its top pick in the Life Sciences & Diagnostic Tools group and maintained a $40.00 price target. Jefferies and Piper Sandler have also maintained their Buy and Overweight ratings respectively on the company.

Furthermore, Guardant Health has announced a partnership with pharmaceutical company Boehringer Ingelheim to seek regulatory approval for Guardant360® CDx, a liquid biopsy test, as a companion diagnostic for zongertinib, Boehringer’s investigational drug for non-small cell lung cancer.

The company has also reported impressive 29.2% revenue growth over the last twelve months. These recent developments highlight the company’s ongoing efforts to expand its services and maintain strong growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.